Penetrium Bioscience announced on Wednesday that it will finalize a new clinical strategy to tackle the issue of resistance to targeted cancer therapies at the American Association for Cancer Research (AACR 2026) conference in San Diego. The company plans to launch Phase 2 clinical trials in the United States.
The global market for targeted cancer therapies has ballooned to approximately 130 trillion KRW (about 88 million USD) as of 2024. Since the early 2000s, groundbreaking treatments like Novartis’s Gleevec, AstraZeneca’s Tagrisso, Pfizer’s Ibrance, and Amgen’s Lumakras have ushered in the era of precision medicine. However, these therapies share a common drawback: diminishing efficacy over time due to drug resistance.
At the conference, Penetrium Bioscience highlighted the root cause of this resistance: the sub-lethal dose problem. This occurs when the dense physical environment surrounding tumors impedes drug penetration, preventing cancer treatments from reaching the minimum concentration needed to eradicate cancer cells.
Dr. Sandip Patel, a renowned expert from the University of California San Diego (UCSD) who has led large-scale basket trials at the National Cancer Institute (NCI), endorsed Penetrium’s environmental normalization approach as a viable solution to the challenges faced by targeted therapies. He has agreed to serve as the principal investigator for the upcoming U.S. Phase 2 trial.
Dr. Patel, along with experts from global clinical research organizations (CROs), recognized Penetrium’s universal mechanism for overcoming common tumor barriers. They designed the world’s first Dual-agnostic Basket Trial to evaluate multiple tumor types and targeted therapies within a single framework.
The company stated that this design aligns with the U.S. Food and Drug Administration’s (FDA) master protocol guidelines. While some regulatory environments apply conservative standards to single indications, the FDA embraces innovative clinical designs, fostering a progressive ecosystem. Penetrium Bioscience aims to conduct combination trials focused on targeted therapies in the U.S., while simultaneously running immunotherapy-based trials approved by South Korean regulators, demonstrating its global potential.
Dr. Kim Taek-seong, Chief Executive Officer (CEO) of Modern Bioscience USA, commented that the FDA leads the world in embracing innovative clinical designs. The thorough review with Dr. Patel and local experts has validated the dual-agnostic basket trial approach. They’re poised to rapidly generate compelling data that could reshape the targeted cancer therapy landscape.
Jin Geun-woo, co-CEO of Penetrium Bioscience, added that as major pharmaceutical companies grapple with the sub-lethal dose problem in their targeted therapies, Penitrium offers a potential solution. Through the strategic trials in both the U.S. and South Korea, it aims to prove that Penitrium can enhance the efficacy of cancer treatments globally and revolutionize cancer therapy.